Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Targeting of Integrin α4/VCAM-1 with AVA4746 Modulates the Redox-Status and Metabolism in ALL and Angiogenesis

Ruan Yongsheng, MD, Enzi Jiang, MD PhD, Hye Na Kim, Heather Ogana, Mo Yang, MD, Deepa Bhojwani, MD, Alan S. Wayne, MD, Yong-Mi Kim, MD MPH, PhD

Blood (2019) 134 (Supplement_1): 3881.

https://doi.org/10.1182/blood-2019-132101

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy

Hye Na Kim, Enzi Jiang, MD PhD, Ruan Yongsheng, MD, Heather Ogana, Nour Abdel-Azim, Justin Le, BS, Annie Luong, Halvard Bonig, MD, Nabil Ahmed, MD, Moghimi Babak, MD, Michael A. Pulsipher, MD, Deepa Bhojwani, MD, Alan S. Wayne, MD, Chintan Parekh, MBBS, Hisham Abdel-Azim, Nora Heisterkamp, Yong-Mi Kim, MD MPH, PhD

Blood (2019) 134 (Supplement_1): 2623.

https://doi.org/10.1182/blood-2019-132131

Published: 2019

Journal Articles

Dual Targeting of PI3Kdelta and BRD4 Sensitizes Acute Lymphoblastic Leukemia to Chemotherapy

Hye Na Kim, Cydney Nichols, Enzi Ji Jiang, MD PhD, Nour Abdel-Azim, Ariana Coba, DOnald L. Durden, MD PhD, Yong-Mi Kim, MD MPH, PhD

Blood (2018) 132 (Supplement 1): 1420.

https://doi.org/10.1182/blood-2018-99-116310

Published: 2018

Journal Articles

Inhibiting Aurora Kinase B Sensitizes B-Cell Acute Lymphoblastic Leukemia to Glucocorticoids

Coralie Poulard, Hye Na Kim, Celine Gagnieux, Karina Kruth, PhD, Mimi Fang, Daniel Gerke, Deepa Bhojwani, MD, Yong-Mi Kim, MD MPH, PhD, Michael R Stallcup, PhD, Miles A. Pufall, PhD

Blood (2017) 130 (Supplement 1): 5113.

https://doi.org/10.1182/blood.V130.Suppl_1.5113.5113

Published: 2017

Journal Articles

CAR T Cell Relapse CD19 Negative ALL Cells Express Integrins and Integrin Blockade Can Prolong Survival In Vivo

Hye Na Kim, Solah Lee, Kristen Fousek, BS, MS, Shuangyue Li, Anne Kim, Junji Watanabe, PhD, Halvard Bonig, MD MA, Nabil Ahmed, MD, Hisham Abdel-Azim, Nora Heisterkamp, PhD, Yong-Mi Kim, MD MPH, PhD

Blood (2017) 130 (Supplement 1): 2601.

https://doi.org/10.1182/blood.V130.Suppl_1.2601.2601

Published: 2017

Journal Articles

Integrin alpha6-Deletion Induces Apoptosis and Src Signaling Changes in Acute Lymphoblastic Leukemia Cells

Eun Ji Gang, MD PhD, Hye Na Kim, Johanna Scott, PhD, Matthew J Oberley, MDPhD, Etan Orgel, MD MS, Steven D. Mittelman, MDPhD, Yao-Te Hsieh, PhD, Markus Muschen, MD, Deepa Bhojwani, MD, Daniel Braas, PhD, Thomas Graeber, PhD, Nora Heisterkamp, PhD, Yong-Mi Kim, MD MPH, PhD

Blood (2017) 130 (Supplement 1): 3878.

https://doi.org/10.1182/blood.V130.Suppl_1.3878.3878

Published: 2017

Journal Articles

Targeting Primary Pre-B Cell Acute Lymphoblastic Leukemia and CD19-Negative Relapses Using Trivalent CAR T Cells

Kristen Fousek, BS, MS, Junji Watanabe, PhD, Ann George, PhD, Xingyue An, BS, Hebatalla Samaha, MS, Shoba Alaska Navai, MD, Tiara T Byrd, PhD, Albert Jang, BS, Hye Na Kim, Sujith Joseph, Matthew Baker, Navin Varadarajan, PhD, Meenakshi G. Hegde, MD, Yong-Mi Kim, MD MPH, PhD, Nora Heisterkamp, PhD, Hisham Abdel-Azim, Nabil Ahmed, MD

Blood (2017) 130 (Supplement 1): 4614.

https://doi.org/10.1182/blood.V130.Suppl_1.4614.4614

Published: 2017

Journal Articles

PI3Kdelta Inhibitor, CAL-101, De-Adheres Primary Pre-B ALL from VCAM-1 and Induces Apoptosis in Primary Pre-B ALL

Sajad Khazal, MD, Enzi Jiang, MD PhD, Stephanie Shishido, Osanna Kosoyan, Kim Hye-Na, Alexa Velasquez, Yao-Te Hsieh, Hisham Abdel-Azim, MD, Ann M Mohrbacher, MD, Akil Merchant, MD, Alan S. Wayne, MD, Nora Heisterkamp, PhD, Yong-Mi Kim, MD MPH, PhD

Blood (2014) 124 (21): 3715.

https://doi.org/10.1182/blood.V124.21.3715.3715

Published: 2014

Journal Articles

VLA4 Blockade In Acute Myeloid Leukemia

Yao-Te Hsieh, Enzi Jiang, MD, PhD, Jennifer Pham, Hye-Na Kim, Hisham Abdel-Azim, MD, Sajad Khazal, MD, Gesine Bug, MD, PhD, Gabriele Spohn, Ph.D., Halvard Bonig, MD, MA, Yong-Mi Kim, MD, MPH, PhD

Blood (2013) 122 (21): 3944.

https://doi.org/10.1182/blood.V122.21.3944.3944

Published: 2013

Journal Articles

The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy

Yao-Te Hsieh, Eun Ji Gang, MD, PhD, Halvard Bonig, MD, MA, Ronald J Biediger, PhD, Peter Vanderslice, PhD, Yong-Mi Kim, MD, MPH, PhD

Blood (2012) 120 (21): 1500.

https://doi.org/10.1182/blood.V120.21.1500.1500

Published: 2012

Journal Articles

Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.

Eun Ji Gang, MD, PhD, Yao-Te Hsieh, Huimin Geng, PhD, Jennifer Pham, Markus Muschen, MD, Adele de Arcangelis, Cheryl L Willman, MD, William L. Carroll, MD, Elisabeth Georges-Labouesse, Halvard Bonig, MD, MA, Yong-Mi Kim, MD, MPH, PhD

Blood (2012) 120 (21): 2565.

https://doi.org/10.1182/blood.V120.21.2565.2565

Published: 2012

Journal Articles

BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia

Christian Hurtz, Katerina Hatzi, PhD, Leandro Cerchietti, MD, Eugene Park, Yong-Mi Kim, MD, MPH, PhD, Parham Ramezani-Rad, Hassan Jumaa, PhD, Martin C Muller, Wolf-Karsten Hofmann, MD, Andreas Hochhaus, MD, Anupriya Agarwal, PhD, Neil Shah, MD, PhD, Ari Melnick, MD, Brian J. Druker, Markus Muschen

Blood (2011) 118 (21): 446.

https://doi.org/10.1182/blood.V118.21.446.446

Published: 2011

Journal Articles

Adjuvant CD49d Blockade Eradicates Chemoresistant ALL

Yao-Te Hsieh, Eugene Park, Enzi Jiang, MD, PhD, Katrin Dauber, Doreen Chudziak, Paul Schaefer, Lars Klemm, Carlton Scharman, Eun-Suk Kang, MD, PhD, Hong-Hoe Koo, MD, PhD, Mignon L. Loh, M.D., Wolf Karsten Hofmann, MD, PhD, Nora Heisterkamp, Markus Muschen, MD, Hiroyuki Shimada, MD, Halvard Bonig, MD, MA, Yong-Mi Kim, MD, MPH

Blood (2010) 116 (21): 869.

https://doi.org/10.1182/blood.V116.21.869.869

Published: 2010

Journal Articles

Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia

Eugene Park, Enzi Jiang, MD, PhD, Yao-Te Hsieh, Lars Klemm, Cihangir Duy, Edward M. Conway, MD, PhD, FRCPC, MBA, Louis M. Pelus, PhD, John Crispino, PhD, Mignon L. Loh, M.D., Eun-Suk Kang, MD, PhD, Hong-Hoe Koo, MD, PhD, Allen Yang, MD, PhD, Nora Heisterkamp, PhD, Michael Kahn, PhD, Markus Muschen, MD, Yong-Mi Kim, MD, MPH

Blood (2010) 116 (21): 3263.

https://doi.org/10.1182/blood.V116.21.3263.3263

Published: 2010

Journal Articles

Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin

Enzi Jiang, MD, PhD, Eugene Park, Cu Nguyen, James Yoon, Yao-Te Hsieh, Mignon L. Loh, M.D., Markus Muschen, MD, Michael Kahn, Yong-mi Kim, MD, MPH

Blood (2010) 116 (21): 3264.

https://doi.org/10.1182/blood.V116.21.3264.3264

Published: 2010

Journal Articles

The Gamma Catenin/CBP Complex Maintains Survivin Transcription In β-Catenin Deficient/Depleted Cancer Cells.

Yong-Mi Kim, MD, MPH, PhD, Hong Ma, Ph.D., Vivian Oehler, MD, Enzi Jiang, MD, PhD, Cu Nguyen, David P. Masiello, MD, Han Liu, Yi Zhao, MD, PhD, Jerald P. Radich, MD, Michael Kahn

Blood (2010) 116 (21): 1218.

https://doi.org/10.1182/blood.V116.21.1218.1218

Published: 2010

Journal Articles

Preclinical Evaluation of Tysabri as a Novel Adjuvant Therapy against Drug Resistant B-ALL.

Yao-Te Hsieh, Enzi Jiang, MD, PhD, Carlton Scharman, Ella Waters, Eugene Park, Asha Kadavallore, Halvard Bonig, MA/MD, Yong-Mi Kim, MD, MPH, PhD

Blood (2009) 114 (22): 3089.

https://doi.org/10.1182/blood.V114.22.3089.3089

Published: 2009

Journal Articles

Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia.

Yong-Mi Kim, MD, MPH, Eugene Park, Colin Lorentzen, Brian De La Torre, Yao-Te Hsieh, Hannah Whang, Lars Klemm, Cu Nguyen, PhD, Michael McMillan, PhD, Jia-Ling Teo, PhD, Markus Muschen, MD, Michael Kahn, PhD

Blood (2007) 110 (11): 1596.

https://doi.org/10.1182/blood.V110.11.1596.1596

Published: 2007

NARROW

Targeting of Integrin α4/VCAM-1 with AVA4746 Modulates the Redox-Status and Metabolism in ALL and Angiogenesis

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy

Dual Targeting of PI3Kdelta and BRD4 Sensitizes Acute Lymphoblastic Leukemia to Chemotherapy

Inhibiting Aurora Kinase B Sensitizes B-Cell Acute Lymphoblastic Leukemia to Glucocorticoids

CAR T Cell Relapse CD19 Negative ALL Cells Express Integrins and Integrin Blockade Can Prolong Survival In Vivo

Integrin alpha6-Deletion Induces Apoptosis and Src Signaling Changes in Acute Lymphoblastic Leukemia Cells

Targeting Primary Pre-B Cell Acute Lymphoblastic Leukemia and CD19-Negative Relapses Using Trivalent CAR T Cells

PI3Kdelta Inhibitor, CAL-101, De-Adheres Primary Pre-B ALL from VCAM-1 and Induces Apoptosis in Primary Pre-B ALL

VLA4 Blockade In Acute Myeloid Leukemia

The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy

Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.

BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia

Adjuvant CD49d Blockade Eradicates Chemoresistant ALL

Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia

Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin

The Gamma Catenin/CBP Complex Maintains Survivin Transcription In β-Catenin Deficient/Depleted Cancer Cells.

Preclinical Evaluation of Tysabri as a Novel Adjuvant Therapy against Drug Resistant B-ALL.

Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only